slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 213,151-213,180
Pages 10,126
Rows per page 30
Component
213,151-213,180 of 303,780
32
Includes detailed footnotes explaining specific adjustments like equity-based profit sharing and merger-related costs.Apollo Global Management | Results Presentation Deck | 41 slides · Apollo Global Management
Conference presentation Investor relations 1 hit
33
Contains four distinct sub-tables detailing revenue, asset management investments, net investments, and accrued performance fee receivables.Apollo Global Management | Results Presentation Deck | 41 slides · Apollo Global Management
Conference presentation Investor relations 1 hit
34
The table shows adjustments for investment gains, insurance liabilities, integration expenses, and stock compensation.Apollo Global Management | Results Presentation Deck | 41 slides · Apollo Global Management
Conference presentation Investor relations 1 hit
35
The slide contains two distinct sub-tables for different asset categories.Apollo Global Management | Results Presentation Deck | 41 slides · Apollo Global Management
Conference presentation Investor relations 1 hit
36
Standard financial disclosure slide defining key performance indicators.Apollo Global Management | Results Presentation Deck | 41 slides · Apollo Global Management
Conference presentation Investor relations 1 hit
37
Standard financial disclosure slide for investor presentations.Apollo Global Management | Results Presentation Deck | 41 slides · Apollo Global Management
Conference presentation Investor relations 1 hit
38
This is a continuation of a definitions slide, listing technical terms alphabetically.Apollo Global Management | Results Presentation Deck | 41 slides · Apollo Global Management
Conference presentation Investor relations 1 hit
39
This is a standard disclosure/glossary slide found in financial reporting decks.Apollo Global Management | Results Presentation Deck | 41 slides · Apollo Global Management
Conference presentation Investor relations 1 hit
41
Apollo Global Management | Results Presentation Deck | 41 slidesApollo Global Management | Results Presentation Deck | 41 slides · Apollo Global Management
Conference presentation Investor relations 1 hit
01
Arbutus Biopharma | Investor Presentation Deck | 28 slidesArbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
02
Arbutus Biopharma | Investor Presentation Deck | 28 slidesArbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
03
The slide uses a two-column layout to present distinct therapeutic focus areas.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution & ApproachLoop · Logic Chain1 hit
04
The slide uses a column-based layout with icons and supporting text to summarize company strengths.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution & ApproachLoop · Logic Chain1 hit
05
The slide uses a Gantt-style chart to show the status of various drug candidates (AB-729, AB-161, AB-101, AB-343) in HBV and COVID-19 programs.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution & ApproachLoop · Logic Chain1 hit
06
The slide uses a four-column layout to structure the disease overview.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Situation & ContextLoop · Logic Chain1 hit
07
Uses a nested circle diagram to represent the patient funnel (Total -> Diagnosed -> Treated).Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Problem & ComplicationLoop · Logic Chain1 hit
08
The slide uses a process-oriented flow diagram to explain the mechanism of action for a combination therapy.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution & ApproachLoop · Logic Chain1 hit
09
The slide highlights the mechanism of action and key clinical/preclinical benefits of the drug candidate.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution & ApproachLoop · Logic Chain1 hit
10
The slide outlines the study structure for a clinical trial, categorizing cohorts by dosage and patient status (HBV DNA +/-).Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
11
Data table includes standard error (SE) values for each mean. Footnote provides specific study parameters.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
12
The slide displays longitudinal data for cohorts E, F, I, J, G, and K, with specific callouts for individual patient outcomes.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
13
The slide displays 8 individual patient charts tracking three biomarkers over 64 weeks. Two patients (53 and 58) show NA retreatment periods.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
14
Data presented at EASL 2022. Shows longitudinal patient data for patients 42, 43, and 48.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
15
The slide uses a bulleted list to present clinical safety findings.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
16
The slide uses a four-column layout to present key findings from a clinical trial.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
17
The slide uses a timeline-based process diagram to illustrate the clinical trial flow.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
18
The slide outlines two distinct study arms involving AB-729, VTP-300, and Nivolumab, with a primary focus on safety and reactogenicity.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
19
The slide details a licensing deal with Qilu Pharmaceutical, including financial terms and partner background.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
20
The slide uses a three-column layout to highlight key value propositions.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
22
Includes a disclaimer at the bottom regarding an FDA clinical hold.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit